neoCARHP
Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)
- NCT04858529 ↗
- Unknown
- Guangdong Provincial People's Hospital
- Deep
We haven't built an HCP commentary report on neoCARHP (THP in HER2-positive breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 39 newest of 47 indexed sources (May 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether carboplatin can be omitted routinely or should be reserved for selected patients
- Whether carboplatin omission affects event-free or recurrence outcomes
- How far neoadjuvant chemotherapy can be de-escalated, including treatment duration
Indexed commentary on neoCARHP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 37 | |
| YouTube | 5 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant TCHP Versus THP in Patients With Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (neoCARHP) : a Randomized, Open-label, Multicenter, Phase III Trial
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Neoadjuvant Therapies for HER2+ Breast Cancer
- Interventions
- investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP); investigator-selected taxane/trastuzumab/pertuzumab (THP)
- Arms
- THP · Experimental
- TCHP · Active comparator
- Enrollment
- 774 (estimated)
- Primary outcomes
- pathological complete response(ypT0/is,ypN0, pCR)
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 30, 2021
- Primary completion
- Apr 30, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT04858529 · updated Nov 7, 2023
Publications
linked from the registry- Gao HF, Ye GL, Lin Y, Huang Q, Dong J, Cao Y, Zhao YX, Chen QJ, Ma SH, Ouyang J, Ye JH, Yang HW, Zhang YQ, Zhang YC, Zhang GL, Li W, Zhang Y, Wu ZY, Lin YY, Zhu T, Zhang LL, Yang CQ, Yang M, Peng H, Chen B, Chen YT, Ji F, Cheng MY, Li JQ, Jiang Z, Wang K. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. J Clin Oncol. 2026 Jun 10;44(17):1587-1596. doi: 10.1200/JCO-25-02176. Epub 2026 Jan 23. PubMed 41576297
- Zhu T, Huang YH, Li W, Wu CG, Zhang YM, Zheng XX, Zhang TF, Lin YY, Liu ZY, Ye GL, Lin Y, Wu ZY, Wang K. A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial. Br J Cancer. 2024 Sep;131(4):692-701. doi: 10.1038/s41416-024-02726-3. Epub 2024 Jun 25. PubMed 38918556